Robin Prince, PhD
Robin Prince is a seasoned medicinal chemist who most recently served as a project co-leader for program and platform initiatives at Arrakis Therapeutics. Prior to Arrakis, Robin supported the development of peripheral and CNS-penetrant kinase inhibitors at Biogen. Over the course of 8 years, she has supported the advancement of multiple clinical candidates (from discovery to IND filing), as well as led discovery teams to identify and validate promising hits for elaboration.
Robin holds a PhD in Chemistry from Harvard University, where she performed her graduate research in Prof. Andrew Myers’ lab, focusing on the synthesis of antibiotics. She graduated from Brandeis University with a B.S. in Chemistry, a B.A. in Biochemistry, and a B.A. in Biology, while also performing research in Prof. Barry Snider’s lab, investigating the total synthesis of a small natural product. She has authored multiple publications, been named co-inventor on numerous patent applications, and has been an active member of the American Chemical Society since 2007.